About this trial
Liver transplantation carries a substantial risk of bleeding, making precise haemostasis control essential, although assessing coagulation remains challenging. Quantra, a bedside viscoelastic testing device using sonorheometric methods, offers an innovative approach to guiding haemostatic management during surgery. The study aims to determine whether a Quantra-guided transfusion can reduce transfusion and bleeding during liver transplantation when compared to a conventional transfusion approach.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 years or older
Patient with ESLD undergoing liver transplantation
Individuals affiliated with or beneficiaries of a social security scheme
Free and informed written consent obtained in writing from the patient, or where applicable from the trusted person/family member/close relative
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Transfusion algorithm based on Quantra®
Biological/VaccineIn addition to routine coagulation tests, a Quantra Qstat® analysis will be performed at baseline (before incision), at the end of native liver dissection, and after unclamping of the venous anastomoses. In the event of bleeding, additional Quantra Qstat® analyses may be conducted until bleeding control is achieved. Transfusion and administration of blood-derived medications will be guided by the results of the Quantra Qstat® analyses.
Conventional transfusion algorithm
Biological/VaccineTransfusion and blood-derived medications will be guided by the results of routine coagulation tests.
Treatment groups
Trial outcomes
Primary outcomes
Fresh Frozen Plasma (FFP) transfusion during liver transplantation surgery
Number of FFP transfused intraoperatively during liver transplantation surgery.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.